Crescent Biopharma Inc (CBIO)

Currency in USD
16.300
-0.730(-4.29%)
Closed·
15.970-0.330(-2.02%)
·
Earnings results expected in 3 days
CBIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
15.96017.200
52 wk Range
8.72027.410
Key Statistics
Prev. Close
16.3
Open
17.15
Day's Range
15.96-17.2
52 wk Range
8.72-27.41
Volume
272.86K
Average Volume (3m)
354.49K
1-Year Change
22.6486%
Book Value / Share
5.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CBIO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
31.000
Upside
+90.18%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Crescent Biopharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 31.000
(+90.18% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Hold---Maintain16/07/2026
Cantor Fitzgerald
Buy---Maintain23/06/2026
Stifel
Buy30.00+84.05%-Maintain23/06/2026
H.C. Wainwright
Hold---Downgrade01/06/2026
Stifel
Buy30.00+84.05%29.00Maintain30/04/2026

Earnings

Latest Release
29/04/2026
EPS / Forecast
-0.70 / -0.88
Revenue / Forecast
1M / --
EPS Revisions
Last 90 days

CBIO Income Statement

Compare CBIO to Peers and Sector

Metrics to compare
CBIO
Peers
Sector
Relationship
P/E Ratio
−4.2x−5.8x−0.4x
PEG Ratio
-0.010.00
Price/Book
3.7x1.4x2.6x
Price / LTM Sales
56.7x59.5x2.9x
Upside (Analyst Target)
84.0%202.0%58.0%
Fair Value Upside
Unlock1.0%9.5%Unlock

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Employees
55

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.33M10.48%70.59M
Other Institutional Investors
38.22M89.52%622.91M
Public Companies & Retail Investors
0.000.00%0.00
Total
42.55M100.00%693.5M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Paragon Therapeutics, Inc.12.10%5,000,00081,500
FMR LLC10.00%4,133,51467,376

People Also Watch

51.66
VECO
-5.35%
92.160
ORKA
+0.23%
13.630
DBVT
-1.66%
19.110
ERAS
-1.19%
10.28
XNDU
-4.37%

FAQ

What Is the Crescent Biopharma (CBIO) Stock Price Today?

The Crescent Biopharma stock price today is 16.300 USD.

What Stock Exchange Does Crescent Biopharma Trade On?

Crescent Biopharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Crescent Biopharma?

The stock symbol for Crescent Biopharma is "CBIO."

What Is the Crescent Biopharma Market Cap?

As of today, Crescent Biopharma market cap is 673.580M USD.

What Is Crescent Biopharma's Earnings Per Share (TTM)?

The Crescent Biopharma EPS (TTM) is -8.047.

When Is the Next Crescent Biopharma Earnings Date?

Crescent Biopharma will release its next earnings report on 30/07/2026.

From a Technical Analysis Perspective, Is CBIO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Crescent Biopharma Stock Split?

Crescent Biopharma has split 1 times.

How Many Employees Does Crescent Biopharma Have?

Crescent Biopharma has 55 employees.

What is the current trading status of Crescent Biopharma (CBIO)?

As of 27/07/2026, Crescent Biopharma (CBIO) is trading at a price of 16.300 USD, with a previous close of 16.300 USD. The stock has fluctuated within a day range of 15.960 USD to 17.200 USD, while its 52-week range spans from 8.720 USD to 27.410 USD.

What Is Crescent Biopharma (CBIO) Price Target According to Analysts?

The average 12-month price target for Crescent Biopharma is 31.000 USD, with a high estimate of 35 USD and a low estimate of 27 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +90.18% Upside potential.

What Is the CBIO After Hours Price?

CBIO's last after hours stock price is 15.970 USD, the stock has decreased by -0.330, or -2.020%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.